Evidence map›Paper›PMID 42080118›Full record

ArticleFrontiers in aging neuroscience2026

Impact of Lewy body and limbic-predominant TDP-43 neuropathology on cognitive and neuropsychiatric trajectory in Alzheimer's disease: a retrospective neuropathological study.

Jarok Koo, Hyungjin Lee, Yunyeong Choi, Kyoungwon Baik, Mincheol Park, Alzheimer’s Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jarok Koo *Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Hyungjin Lee *Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Yunyeong ChoiChung-Ang University College of Medicine, Seoul, Republic of Korea.
Kyoungwon BaikAnam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
Mincheol ParkChung-Ang University College of Medicine, Seoul, Republic of Korea.
Alzheimer’s Disease Neuroimaging Initiative

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Alzheimer's disease (AD) is the leading cause of neurodegenerative dementia, and mixed neuropathological changes including Lewy body (LB-NC) and TDP-43 (LATE-NC) are commonly observed in patients with AD. We examined the baseline cross-sectional and longitudinal effects of these co-pathologies on cognitive and neuropsychiatric trajectories. Methods: We investigated 77 participants who had available autopsy data and showed intermediate to high levels of AD neuropathological change from the ADNI database. Participants were categorized based on the presence or absence of LB-NC or LATE-NC. The impact of LB-NC and LATE-NC on baseline and longitudinal clinical features was assessed using linear regression and linear mixed-effects models, respectively. Results: Thirty-eight (49.4%) had LB-NC, and 39 (50.6%) had LATE-NC. At baseline, the presence of LB-NC was not associated with cognitive function or neuropsychiatric symptoms, whereas the presence of LATE-NC was associated with better trail-making test performance and less severe sleep disturbance. Longitudinally, the presence of LB-NC was associated with faster cognitive decline in global cognitive function, memory, language, and executive function, whereas the presence of LATE-NC was associated with a slower decline in language function. Neither LB-NC nor LATE-NC influenced the longitudinal trajectory of neuropsychiatric symptoms. Conclusion: Among patients with pathologically confirmed AD, the presence of LB-NC accelerated cognitive decline, whereas the presence of LATE-NC was not associated with overall cognitive trajectories. Investigating comorbid pathologies is essential for prognostic stratification and the development of personalized therapeutic strategies in AD.

Indexed as

Alzheimer’s diseaseLewy body diseaselimbic-predominant age-related TDP-43 encephalopathyprognosisTDP-43

Identifiers

PMID42080118
PMCPMC13132858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.